Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 74Colonic Neoplasms 31Rectal Neoplasms 29Neoplasm Metastasis 16Stomach Neoplasms 12Pancreatic Neoplasms 12Esophageal Squamous Cell Carcinoma 8Small Cell Lung Carcinoma 7Neoplasms 6Esophageal Neoplasms 6Rhabdomyosarcoma 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Uterine Cervical Neoplasms 3Sarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Cholangiocarcinoma 3Biliary Tract Neoplasms 3Rectal Diseases 2Neuroblastoma 2Neoplasms by Histologic Type 2Intestinal Diseases 2Hepatoblastoma 2Gastrointestinal Diseases 2Ganglioneuroblastoma 2Digestive System Diseases 2Colorectal Cancer Metastatic 2Colorectal Adenocarcinoma 2Colonic Diseases 2

Interventions

pembrolizumab 4Gemcitabine 4padeliporfin 3napabucasin 3Pemetrexed 3Paclitaxel 3Drug Therapy 3Cisplatin 3Carboplatin 3130-nm albumin-bound paclitaxel 3ribociclib 2palbociclib 2Mitomycin 2Gonadotropin-Releasing Hormone 2Fluorouracil 2Bevacizumab 2Anastrozole 2Albumin-Bound Paclitaxel 2AZD9833 2valrubicin 1selinexor 1pralsetinib 1patritumab 1palladium-bacteriopheophorbide 1linifanib 1ipatasertib 1enfortumab vedotin 1camrelizumab 1atezolizumab 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms by Site × Irinotecan × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡